ctDNA for Early Detection of Recurrence in Melanoma
Conditions: Melanoma Sponsors: Herlev and Gentofte Hospital; Danish Cancer Society; Danish Cancer Research Foundation; DCCC ctDNA Research Center; CAG in Cancer immunotherapy Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
Conditions: Melanoma Interventions: Drug: fianlimab; Drug: cemiplimab; Drug: relatlimab+nivolumab Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Conditions: Uveal Melanoma Interventions: Drug: Tebentafusp Sponsors: European Organisation for Research and Treatment of Cancer - EORTC; Northwell Health Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Study of MGC026 in Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer Interventions: Biological: MGC026 Dose Escalation; Biological: MGC026 Dose for Expansion Sponsors: MacroGenics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab; Drug: Nivolumab Sponsors: The Netherlands Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Melanoma; Lung Neoplasms; Head and Neck Neoplasms Interventions: Drug: KSQ-001EX; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: M.D. Anderson Cancer Center; KSQ Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
ERK Inhibitor JSI-1187 in Advanced Solid Tumors
Conditions: Solid Tumor; NSCLC; Melanoma Interventions: Drug: JSI-1187 Sponsors: JS InnoPharm, LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet
Conditions: Melanoma Stage Iv; Metastatic Melanoma Interventions: Behavioral: Mediterranean Diet Intervention Sponsors: University Hospital Rijeka Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Conditions: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer Interventions: Drug: Leflunomide; Drug: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab Sponsors: N.N. Petrov National Medical Research Center of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Skin Tumor Biomarkers by Mass Spectrometry Imaging
Conditions: Skin Cancer; Squamous Cell Carcinoma; Basal Cell Carcinoma; Non-melanoma Skin Cancer Interventions: Other: Biopsy Sponsors: Bispebjerg Hospital; University of Copenhagen Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Conditions: Cutaneous Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma Interventions: Drug: Eutectic Mixture of Local Anesthetics; Drug: Placebo Administration; Other: Questionnaire Administration Sponsors: Ohio State University Comprehensive Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma
Conditions: Melanoma; Melanoma, Skin Sponsors: AI Labs Group S.L; Servicio Vasco de Salud Osakidetza, Spain; Osakidetza; Hospital de Basurto; Hospital de Cruces Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Conditions: Melanoma Interventions: Biological: Vusolimogene oderparepvec (RP1) Sponsors: Yana Najjar; Replimune Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Conditions: Advanced Melanoma Interventions: Biological: T3011 Sponsors: Shanghai Pharmaceuticals Holding Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
Allogeneic Gammadelta T Cells Combined With Interferon- α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
Conditions: Melanoma Interventions: Biological: Ex-vivo expanded allogeneic γδ T cells; Drug: Recombinant human interferon α1b; Drug: Pembrolizumab Sponsors: Xijing Hospital; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
